Alkeran (Melphalan) - Summary

ALKERAN SUMMARY

ALKERAN (melphalan), also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent which is active against selective human neoplastic diseases.

ALKERAN Tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

ALKERAN NEWS HIGHLIGHTS

Media Articles Related to Alkeran (Melphalan)

melphalan-oral, Alkeran
Source: MedicineNet Amyloidosis Specialty [2005.03.02]

Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
Source: MedPage Today Hematology/Oncology [2008.08.27]

New England Journal Of Medicine Publishes Phase III Results Of VELCADE(R) (Bortezomib) For Injection In Previously Untreated Multiple Myeloma Patients
Source: Blood / Hematology News From Medical News Today [2008.08.29]

more>>

Published Studies Related to Alkeran (Melphalan)

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. [2008.05.27]

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. [2007.10.06]

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. [2007.09.13]

Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. [2006.11]

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. [2006.09.01]

more>>

Clinical Trials Related to Alkeran (Melphalan)

Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma [Terminated]

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients [Completed]

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor [Active, not recruiting]

Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) [Active, not recruiting]

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. [Active, not recruiting]

more>>